INTRODUCTION {#S1}
============

Despite reduced prevalence, tobacco use remains the largest cause of preventable mortality both in the US and worldwide\[[@R1], [@R2]\]. And although more than half of American smokers attempt to quit every year, only 6% succeed\[[@R3]\]. Currently, three medications ---varenicline, nicotine replacement therapy and bupropion---are prescribed to aid smoking cessation with modest success\[[@R4]\], but the heavy burden of tobacco-related disease warrants pursuing further pharmacotherapy targets.

Nicotine is extensively metabolized. In most smokers, the large majority of nicotine (70--80%) is metabolized to cotinine, the product of cytochrome P450 2A6 (CYP2A6) -catalyzed oxidation\[[@R5], [@R6]\] , but two further pathways also contribute to human hepatic nicotine metabolism: *N*-glucuronidation catalyzed by the UDP-glucuronsyltransferase UGT2B10, and *N*-oxidation by the flavin monooxygenase FMO3. Variation in *in vivo* nicotine metabolism is strongly genetically determined and significantly predicts smoking-related behaviors including cessation\[[@R7]--[@R9]\]. Specifically, *CYP2A6* is among the few loci consistently associated with cigarette consumption and related pulmonary disease in genome-wide association studies (GWAS)\[[@R10]--[@R12]\]. But, importantly, *CYP2A6*'s influence on smoking behavior is primarily related to cigarette consumption among dependent smokers\[[@R13]\] unlike functional variation in the *CHRNA5* nicotinic acetylcholine receptor subunit gene, which is associated with consumption and dichotomous nicotine dependence\[[@R14]--[@R16]\].

On average less than 7% of total nicotine equivalents (the sum of nicotine and six metabolites) are typically excreted as nicotine-*N*-oxide\[[@R17]--[@R19]\]. However, a notable feature of the *FMO*s is their expression and activity in the human brain\[[@R20], [@R21]\], where CYP2A6 is not detected\[[@R22]\]. *FMO3* is also highly polymorphic, including several common amino acid altering variants with reported substrate specific consequences\[[@R23]\]. The *FMO3* polymorphisms that determine heritable differences in nicotine *N*-oxidation are not established; here we describe experiments that evaluated nicotine *N*-oxidation *in vivo* to identify common *FMO3* alleles associated with altered nicotine metabolism. We also pursued the mechanisms by which these variants alter enzymatic activity, and the mechanisms by which variation in nicotine *N*-oxidation may influence nicotine dependence.

MATERIALS AND METHODS {#S2}
=====================

Human Subjects {#S3}
--------------

The study complies with the Code of Ethics of the World Medical Association. Written informed consent from participants and approval from the appropriate institutional review boards was obtained. Metabolism experiment participants were recruited from the Collaborative Genetic Study of Nicotine Dependence (COGEND)\[[@R16], [@R24]\]. Subjects in the clinical phenotypes experiments were European Americans in the University of Wisconsin Transdisciplinary Tobacco Use Research Center (UW-TTURC) cessation trials\[[@R25]--[@R27]\].

Clinical nicotine disposition {#S4}
-----------------------------

Nicotine was administered and plasma collected 240 minutes later, as described \[[@R24]\]. We previously demonstrated the validity of single time point measures of nicotine metabolites as correlates of genetic variation \[[@R24], [@R28]\]. Nicotine-*N*-oxide and d~2~-nicotine-*N*-oxide were analyzed by liquid chromatography tandem mass spectrometry as previously \[[@R19]\]. Selective reaction monitoring was carried out for nicotine-*N*-oxide (*m/z* 179 → 130 and *m/z* 179 → 117), d~2~-nicotine *N*-oxide (*m/z* 181 → 131 and *m/z* 181 → 117) and the internal standard d~3~-nicotine-*N*-oxide (*m/z* 182 → 130 and *m/z* 182 → 117). Percent of total nicotine converted to nicotine-*N*-oxide was calculated as nicotine-*N*-oxide/(nicotine + nicotine-*N*-oxide + cotinine + *trans*-3\'-hydroxycotinine + nicotine-glucuronide). Nicotine, cotinine, *trans*-3\'-hydroxycotinine and nicotine-glucuronide were previously reported \[[@R24], [@R28]\].

Genotyping and haplotype determination {#S5}
--------------------------------------

Metabolism experiment subjects were genotyped and a nicotine metabolism metric based on *CYP2A6* genotype determined as previously reported\[[@R16], [@R24], [@R28], [@R29]\]. *FMO3* haplotypes were determined using PHASE version 2.1.1\[[@R30]\]. In all other subjects *FMO3* SNPs were genotyped by the Center for Inherited Disease Research at Johns Hopkins University using the Illumina Omni2.5 microarray ([www.illumina.com](www.illumina.com)), with data cleaning led by the GENEVA Coordinating Center at the University of Washington\[[@R29]\]. All SNPs analyzed conformed to Hardy-Weinberg equilibrium.

Gene expression and splicing in human liver and brain {#S6}
-----------------------------------------------------

Genomic DNAs and cDNAs were previously prepared from de-identified normal liver biopsy samples and postmortem cerebellum samples of European descent\[[@R31], [@R32]\]. cDNAs from cultured primary human brain astrocytes and endothelial cells were prepared using the Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA) and EasyScript cDNA synthesis kit (Lamda Biotech, Sovereign CT, USA). Human neuron cDNA was purchased from Sciencell Research Laboratories (Carlsbad, CA, USA). Gene expression and splicing were assessed by real-time PCR using an ABI-7900HT Fast real-time PCR system ([Supplemental Methods](#SD1){ref-type="supplementary-material"}).

Recombinant FMO3 expression {#S7}
---------------------------

Sequence-verified pVL1393 vectors containing full length *FMO3* cDNA with variants were purchased from Life Technologies (Carlsbad, CA, USA). Protein was expressed as previously \[[@R33]\] at a multiplicity of infection of 8, with 10 μg/ml FAD (Sigma, St. Louis, MO, USA) added 12 hrs after infection. Supersomes expressing reference FMO3 and FMO1 were purchased from Corning (Corning, NY, USA). FAD content was quantified fluorimetrically\[[@R34]\] and used as a measure of FMO holoenzyme content to calculate k~cat~ values. All protein concentrations were determined by Bradford assay.

Cell Culture {#S8}
------------

Cryopreserved primary astrocytes and endothelial cells isolated from human brain (cerebral cortex) were acquired from Sciencell Research Laboratories. Astrocytes (1 x 10^6^ cells, passage 2) were initially cultured on poly-L-lysine coated (2 μg/cm^2^) T-75 flasks in complete astrocyte medium (Sciencell) and grown until confluency. Endothelial cells (5 x 10^5^ cells, passage 1) were cultured on a bovine fibronectin coated (2μg/cm^2^) T-25 flask in complete endothelial cell medium (Sciencell) and cultured until confluency.

Liver, brain, and cultured astrocyte in vitro nicotine metabolism {#S9}
-----------------------------------------------------------------

Cerebral cortex from a 58 year-old Caucasian male flash-frozen 5.5 hours postmortem was obtained from the National Disease Research Interchange (NDRI), Philadelphia PA, USA. Microsomes were prepared ([Supplemental Methods](#SD1){ref-type="supplementary-material"}) and initial experiments determined an appropriate incubation time and microsomal protein concentrations that yielded metabolic activity within a linear range. Metabolites were analyzed by liquid chromatography tandem mass spectrometry ([Supplemental Methods](#SD1){ref-type="supplementary-material"}) and quantified using the ratio of metabolite to internal standard, subtracting background from control incubations (without NADPH), and using calibration curves. Further control incubations included with boiled protein or without protein ([Supplemental Figure S1](#SD1){ref-type="supplementary-material"}).

Nicotine-N-oxide agonism and modulation of neuronal nicotinic acetylcholine receptors {#S10}
-------------------------------------------------------------------------------------

Human α4β2 neuronal nicotinic acetylcholine receptors were expressed in *Xenopus* oocytes following a protocol approved by the Washington University in St. Louis Animal Care and Use Committee ([Supplemental Methods](#SD1){ref-type="supplementary-material"}). The cRNAs were produced using mMessage mMachine (Ambion, Austin, TX, USA). Oocytes were injected with a total of 18--20 ng of cRNA in a final volume of 40--60 nl, and incubated in ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~, 1 mM MgCl~2~, 2.5 mM Na pyruvate, 5 mM HEPES; pH 7.4) at 16 °C. Oocytes were used within 2--3 days after injection. To bias receptor stoichiometries, a 9-fold excess of the α4 or β2 subunit cRNA was injected, with stoichiometry verified by sensitivity to acetylcholine (ACh)\[[@R35]\]. Electrophysiological experiments were conducted using the two-electrode voltage clamp technique ([Supplemental Methods](#SD1){ref-type="supplementary-material"}).

Statistical analysis {#S11}
--------------------

Statistical analyses of pharmacogenetic data were performed using 'R' (Vienna, Austria). Metabolism phenotypes analyzed are fractions of deuterated (d~2~)-nicotine or non-deuterated (d~0~)-nicotine equivalents converted to d~2~ nicotine-*N*-oxide or d~0~ nicotine-*N*-oxide respectively, i.e. nicotine-*N*-oxide/(nicotine + nicotine-*N*-oxide + cotinine + *trans*-3\'-hydroxycotinine + nicotine-glucuronide). Valid measurements below the limits of detection were assumed to be zero. For regression analyses, genetic variables were treated as previously described\[[@R24], [@R28]\]. Current smoking was defined by a mean d~0~-cot \>2ng/ml. Measures of statistical significance are not altered to correct for multiple testing. Genetic associations with smoking phenotypes were tested using a linear model with genotype coded additively and sex, age, and study as covariates. In tests of the Wisconsin Index of Smoking Dependence Motives (WISDM) PDM scale the WISDM Secondary Dependence Motives subscale was used as a covariate. Michaelis-Menten parameters for recombinant enzyme experiments were determined by nonlinear regression using SigmaPlot (Systat Software, San Jose CA, USA).

RESULTS {#S12}
=======

*FMO3* haplotypes associated with nicotine *N*-oxidation {#S13}
--------------------------------------------------------

*FMO3* haplotypes defined by the five *FMO3* coding SNPs common in Europeans (minor allele frequency ≤2%) were determined in 170 subjects with measurements for deuterated nicotine metabolites ([Supplemental Table S2](#SD4){ref-type="supplementary-material"}). We did not identify any subjects with the reportedly common *FMO3* variant N61K, but this variant has never been found in studies of trimethylaminuria, nor by an exome sequencing project including \>4,000 European American genomes\[[@R36]\]. Among our subjects, 59 were current smokers with non-deuterated nicotine-*N*-oxide measurements. The mean plasma concentration of non-deuterated nicotine-*N*-oxide in these smokers was 29.4 ± 22.3 pmol/ml (5.2 ± 4.0 ng/ml). The percent of oral deuterated nicotine converted to nicotine-*N*-oxide after four hours was highly correlated with the percent of *ad libitum* smoked nicotine converted to *N*-oxide in these subjects (R^2^=0.82). The dominant indirect effect of *C*-oxidation upon the percent of nicotine remaining available for conversion to *N*-oxide is demonstrated by the strong association between *CYP2A6* genotype and measures of *N*-oxidation. Overall *CYP2A6* genotype variables account for 34% (R^2^=0.340, n=170) of the variance in the percent of oral nicotine converted to *N*-oxide and 37% (R^2^=0.367, n=59) of the variance in the percent of *ad libitum* smoked nicotine converted to *N*-oxide.

Using the most common *FMO3* haplotype (1) as the reference, in a multivariate model including *CYP2A6* genotype variables, the third most common haplotype (haplotype 3, K158; G308) defined by the minor allele of rs2266780, is significantly associated with reduced *N*-oxidation of both oral nicotine and ad-libitum smoked nicotine (p=3.3x10^−5^ and p=5.6x10^−6^ respectively, [Table 1](#T1){ref-type="table"}). rs2266780 is also significantly associated with reduced nicotine *N*-oxidation when tested individually (p=0.01 and p=0.002 respectively). In the same multivariate models, *FMO3* haplotype 5 is also significantly associated with reduced *N*-oxidation ([Table 1](#T1){ref-type="table"}), although these associations do not reach significance in single-variable analyses. After accounting for *CYP2A6* genotype, rs2266780 alone explained 8.5% (R^2^=0.085) and 21.6% (R^2^=0.216) of the remaining variance in the percent of nicotine-*N*-oxide for oral and smoked nicotine, respectively. Common *FMO3* haplotypes 2 (K158) and 4 (M257) were not significantly associated with altered nicotine-*N*-oxidation relative to the reference haplotype ([Table 1](#T1){ref-type="table"}). Neither current smoking nor sex was significantly associated with altered nicotine *N*-oxidation, consistent with previous reports\[[@R37]\]. *UGT2B10* haplotypes\[[@R28]\] were also not associated.

Although *FMO3* genotype demonstrates a significant influence on *in vivo* nicotine *N*-oxidation, this pathway represents a small fraction of overall hepatic nicotine metabolism (4--10% of excreted nicotine equivalents\[[@R5], [@R19]\]). While we find *CYP2A6* genotype explains the majority (58%) of the variance in total oral nicotine metabolism after four hours (metabolism of nicotine to all measured metabolites, called nicotine equivalents), *FMO3* haplotypes explain less than 1% of that variance. However, relative to the small amount of nicotine typically converted to *N*-oxide, the impact of rs2266780 genotype (defining haplotype 3) is great. On average 1.6 ± 1.3% of deuterated and 1.3 ± 0.9% of non-deuterated nicotine equivalents were present as nicotine-*N*-oxide in rs2266780 major allele homozygotes compared to only 0.7 ± 0.4% and 0.4 ± 0.1% respectively in minor allele homozygotes. Thus, less than half as much nicotine *N*-oxidation occurs in homozygotes for the reduced function *FMO3* haplotype than in individuals homozygous for the reference haplotype (p=5.4x10^−3^ and 3.9x10^−6^ respectively, [Figure 1](#F1){ref-type="fig"}).

Nicotine *N*-oxidation by variant recombinant FMO3 enzymes {#S14}
----------------------------------------------------------

One potential explanation for *FMO3* variant effects on clinical nicotine *N*-oxidation is altered FMO3 catalytic activity. Four versions of the FMO3 enzyme corresponding to the reference allele, K158, G308, and K158;G308 haplotypes were expressed to assess their relative nicotine *N*-oxidation activity *in vitro*. However, we did not observe a reduction in the nicotine-*N*-oxidation activity of the variant FMO3s relative to the reference allele *in vitro* ([Supplemental Table S3](#SD4){ref-type="supplementary-material"}). The product of FMO3-mediated nicotine oxidation is overwhelmingly the *trans* rather than the *cis* stereoisomer. This was true among our four FMO3 haplotypes and commercially available microsomes containing the reference allele (≈ 79:1), similar to previous reports\[[@R38]\]. Incubations with human liver microsomes also primarily produced the *trans* isomer (ratio ≈ 53:1). Interestingly, we also found that recombinant FMO1-containing microsomes overwhelmingly produce the *cis* isomer (≈ 30:1). This suggests nicotine as a convenient probe to distinguish between FMO3 and FMO1 activities.

Haplotypes associated with aberrant *FMO3* mRNA splicing in liver and brain {#S15}
---------------------------------------------------------------------------

Another potential mechanism of genetically-determined variation in FMO3 activity is altered *FMO3* mRNA splicing. Aberrant splicing of *FMO3* mRNA was previously reported in multiple adult and fetal human tissues; these events result in the omissions of the third and seventh exons, leading to frame-shifts and premature stop codons in the aberrantly spliced mRNAs\[[@R39]\]. Custom splicing assays were used to determine the relative amounts of exon skipping of *FMO3* exons 3 or 7 in cDNAs from genotyped European American liver biopsy samples. Only rs2266780 (E308G) was independently associated with relative levels of *FMO3* cDNAs lacking exons 3 or 7 (p\<10^−16^, [Supplemental Figure 2](#SD2){ref-type="supplementary-material"}). These differences equate to greater than 14-fold and 6-fold increases in transcripts lacking exons 3 and 7 respectively. We also repeated the experiments in cDNAs from an unrelated set of human cerebellum samples and found a similarly unequivocal difference (p=6.5x10^−9^). PCR amplification using the primers from the original study\[[@R39]\] confirmed that the products previously reported are associated with the rs2266780 minor allele ([Figure 2](#F2){ref-type="fig"}). rs2266780 is in high linkage disequilibrium (R^2^ ≤ 0.95 in Europeans) with at least eighteen reported intronic SNPs in the *FMO3* gene, but none of these are strongly predicted to affect splicing *in silico*.

We did not detect significant differences in overall *FMO3* transcript expression either in liver or cerebellum samples using TaqMan gene expression assays (data not shown), possibly due to the difficulty of detecting such stable differences in liver biopsy and brain autopsy samples and the demonstrated large effects of diet on *FMO3* mRNA expression\[[@R40]\]. However *FMO3* was detected in all of the liver and cerebellum samples tested with expression levels approximately six hundred-fold higher in liver than in cerebellum, similar to prior reports\[[@R20]\].

*FMO3* genotype associated with nicotine dependence {#S16}
---------------------------------------------------

Despite the modest role of *N*-oxidation to hepatic nicotine metabolism, prior studies have indicated a potential association between *FMO* genotype and smoking behaviors\[[@R41]--[@R43]\]. Therefore, we tested for an association between rs2266780 (E308G) and cigarette consumption and nicotine dependence in a well-ascertained sample of European Americans seeking smoking cessation treatment. Interestingly, we found a significant association (p=0.0036, n=1558) between rs2266780 and nicotine dependence as measured by the Fagerström Test of Nicotine Dependence (FTND). rs2266780 was not significantly associated with cigarette consumption, whether measured as cigarettes per day or using a biomarker of cigarette smoke exposure, exhaled carbon monoxide (p\>0.2). Other *FMO3* variants were not associated with nicotine dependence or cigarette consumption.

The FTND contains six questionnaire items that measure physical dependence and tolerance on an overall 0--10 scale. Analyses of these items showed that the association between rs2266780 and FTND is driven by item 1; rs2266780 was not significantly associated with other items. Item 1, the 'time to first cigarette', elicits information on the time interval a smoker reports between waking in the morning and lighting the first cigarette; the minor allele of rs2266780 is associated with a robust increase in this measure (−0.13 per allele on a 0--3 scale, p=9.0x10^−4^). Among FTND items, time to first cigarette has been demonstrated to be the most informative metric of heritable factors that influence nicotine dependence\[[@R44]\], and distinct from overall cigarette consumption\[[@R45], [@R46]\]. 31% of rs2266780 major allele homozygotes reported typically smoking within the first 5 minutes after awakening, while only 13% of rs2266780 minor allele (haplotype 3) homozygotes reported the same urgency to smoke ([Figure 3](#F3){ref-type="fig"}).

We subsequently tested and found a significant association (p=0.006) between rs2266780 and The Wisconsin Index of Smoking Dependence Motives (WISDM) Primary Dependence Motives (PDM) scale. The PDM measures core dimensions of dependence characterized by strong craving, perceived loss of control over smoking, and an inability to tolerate the passage of time without smoking; it is especially predictive of smoking cessation.\[[@R47], [@R48]\].

To determine whether *FMO3* genotype accounts for variance in FTND and PDM independent of other predictive genetic variables\[[@R29]\], we ran multivariable competitive regression models with rs2266780, rs16969968, the key *CHRNA5* variant, and a previously described nicotine metabolism metric based on *CYP2A6* genotype\[[@R13], [@R29]\]. These models reveal that the *FMO3* variant independently predicts variance in the FTND total score (p=0.009), time to first cigarette (p=0.002), and WISDM PDM scale (p=0.027). *CHRNA5* and *CYP2A6* did not significantly independently predict variance in either the FTND total score or time to first cigarette, but all three genes made independent contributions to the prediction of the WISDM PDM scale (p-values =0.027--0.045).

Nicotine *N*-oxidation in human brain and astrocytes {#S17}
----------------------------------------------------

The association between nicotine dependence and the reduced-function allele led us to investigate novel potential mechanisms for FMO3's influence. Although *FMO3* and *FMO1* mRNAs are expressed in the human brain\[[@R20]\], evidence for FMO activity in the human brain is limited\[[@R21], [@R49]\]. To determine whether nicotine *N*-oxidation occurs in the brain we prepared microsomes from human autopsy cerebral cortex tissue, as well as from primary cultured human astrocytes, and from whole mouse brains. Cultured astrocytes were chosen because of the reported preferential expression of *FMO1* in mouse astrocytes relative to other brain cell types (*FMO3* is not reported expressed at detectable levels in any mouse brain cell type)\[[@R50]\]. We attempted to detect *FMO3* mRNA in human primary cultured astrocytes, as well as in human cultured primary neurons and brain endothelial cells, but found the level of expression was below the detection limits of our assay.

Nicotine *N*-oxidation activity was detected in human brain tissue ([Supplemental Figure S1](#SD1){ref-type="supplementary-material"}). Microsomes were incubated with nicotine or benzydamine, a common FMO substrate and *N*-oxide metabolites were detected for both substrates (benzydamine data not shown). Primary human astrocyte and cerebral cortex microsomes both produce *trans* and *cis* nicotine-*N*-oxide at ratios of approximately 4:1 and 1:1 respectively (at 5mM nicotine, [Table 2](#T2){ref-type="table"}), indicating the activities of both FMO3 and FMO1. This is in contrast to mouse brain microsomes, which overwhelmingly produce *cis* nicotine-*N*-oxide. Production of *cis* nicotine-*N*-oxide by human brain microsomes followed classic Michaelis--Menten kinetics, but the production of the *trans* isomer was non-saturable ([Supplemental Figure S2](#SD2){ref-type="supplementary-material"}) as previously reported for recombinant FMO3\[[@R41]\]. Microsomes prepared from different passages of cultured primary astrocytes (passages 3--7) did not show a reduction in FMO activity.

Activation and modulation of α 4β2 nicotinic acetylcholine receptors by *trans*-nicotine-*N*-oxide {#S18}
--------------------------------------------------------------------------------------------------

An alternative hypothesis to explain the association between *FMO3* genotype and time to first cigarette would be that nicotine-*N*-oxide, whether generated in the liver or brain, has pharmacological activity relevant to tobacco use, such as a direct effect on neuronal nicotinic acetylcholine receptors. Therefore, we measured direct activation and modulation of currents elicited by ACh in human α4β2 nicotinic receptors expressed in *Xenopus* oocytes. In receptors expressed in the 3:2 (α4:β2) stoichiometry, exposure to 200 μM *trans*-nicotine-*N*-oxide resulted in small (peak amplitude: 87 ± 10 nA, mean ± SEM, n = 8 cells) inward currents. Each cell was also tested with a saturating concentration (1 mM) of ACh. The relative peak response to *trans*-nicotine-*N*-oxide was 1.7 ± 0.3% of the response to ACh. Sample current traces are shown in [Figure 4A](#F4){ref-type="fig"}.

Co-application of *trans*-nicotine-*N*-oxide modulated current responses to ACh. The (α4)~3~(β2)~2~ receptors activated by 1 μM ACh (approximately EC~3~) in the presence of 200 μM *trans*-nicotine-*N*-oxide showed a mean peak response of 44 ± 5% (n = 5) of control ([Figure 4A](#F4){ref-type="fig"}). The concentration-response data for inhibition of currents elicited by 1 μM ACh are shown in [Figure 4C](#F4){ref-type="fig"}. Currents from receptors activated by 1 mM ACh (a saturating concentration) were not modulated by 200 μM *trans*-nicotine-*N*-oxide (98 ± 2% of control, 4 cells, P\>0.4, paired t-test). We infer that the inhibitory effect is competitive by nature.

The (α4)~2~(β2)~3~ receptors exhibit higher sensitivity to ACh, and changes in modulation by Zn^2+^ and Ca^2+^ permeability compared to (α4)~3~(β2)~2~ receptors\[[@R35]\]. To increase assembly of (α4)~2~(β2)~3~ receptors, we injected oocytes with an excess of β2 subunit cRNA (see Methods). The resulting receptors showed larger direct activation (5.7±1.1% of the response to saturating ACh; n = 5) compared to (α4)~3~(β2)~2~ receptors (P \< 0.01; two-sample t-test) in the presence of 200 μM *trans*-nicotine-*N*-oxide. Co-application of *trans*-nicotine-*N*-oxide resulted in depressed peak response. Sample current traces are shown in [Figure 4B](#F4){ref-type="fig"}. The inhibitory effect of the drug was similar for (α4)~3~(β2)~2~ and (α4)~2~(β2)~3~ receptors ([Figure 4C](#F4){ref-type="fig"}).

DISCUSSION {#S19}
==========

In this first comprehensive analysis of *FMO3* genotype and *in vivo* nicotine *N*-oxidation, we provide strong evidence that a common haplotype (K158; G308) is associated with significantly reduced activity. It was our hypothesis that by precisely determining the *FMO3* polymorphisms that affect nicotine *N*-oxidation we might refine a genetic model of nicotine metabolism\[[@R13], [@R24], [@R29]\] and see a modest improvement in its prediction of cigarette consumption over a model based on *CYP2A6* genotype alone. However, to our surprise, we discovered a robust association between the reduced-function *FMO3* haplotype and reduced nicotine dependence as defined by the FTND. In particular, we find a striking relationship with longer time to first cigarette, demonstrated as the most informative measure of heritable factors from the FTND\[[@R44]\].

Evidence that differences in cytochrome P450 enzyme activity in the brain influences substance abuse phenotypes is scant, but the activity of FMOs in the brain is well established \[[@R21]\] and we have now demonstrated nicotine *N*-oxidation in human brain microsomes. A prominent role for FMO3-mediated nicotine metabolism in the brain could explain the association with nicotine dependence and time to first cigarette. In the absence of CYP2A6 activity in the brain\[[@R22]\], differences in *N*-oxidation may determine a large portion of the variance in local nicotine clearance, as the reduced-activity *FMO3* allele causes a two-fold decrease in nicotine *N*-oxidation in liver.

A relatively straightforward explanation for *FMO3*'s influence on nicotine dependence is via heritable differences in nicotine clearance, perhaps locally in the brain; but it is also possible that differences in levels of the metabolite, nicotine-*N*-oxide, are responsible. While the modest response elicited by *trans*-nicotine-*N*-oxide *in vitro* probably rules out direct activation of α4β2 receptors by nicotine-*N*-oxide as an important mechanism, the significant inhibition of receptor activation by ACh in the presence of the metabolite warrants further study. In particular, we are interested to understand how nicotine-*N*-oxide may modulate the activity of receptors containing the α5 subunit, demonstrated to influence nicotine-related phenotypes.

Selective inhibition of CYP2A6 has been investigated as a potential strategy to improve the bioavailability of nicotine, but selective inhibition of FMO activity might lengthen nicotine perdurance specifically in the brain, the site of nicotine's pharmacological activity associated with dependence, while avoiding increased peripheral effects and risk for cardiovascular events. Complete *FMO3* deficiency in humans is not associated with symptoms other than trimethylaminuria and therefore FMO inhibition may allow a wide therapeutic window. Furthermore, the results reported here indicate that differences in FMO3 activity influence aspects of nicotine dependence beyond levels of consumption, suggesting that targeting FMOs may have other advantages over more broadly targeting hepatic nicotine metabolism as a smoking cessation pharmacotherapy.
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======================

We would like to thank Dr. Jeffery Milbrandt and his lab for their advice and assistance. We acknowledge the use of tissues procured by the National Disease Research Interchange (NDRI) with support from NIH grant 2 U42 OD011158. The Collaborative Genetic Study of Nicotine Dependence was supported by National Cancer Institute grant P01 CA089392. The University of Wisconsin Transdisciplinary Tobacco Use Research Center was supported by National Institute on Drug Abuse grant P50 DA019706 and National Cancer Institute grant P50 CA084724 (TBB). This work was also supported by the National Institute on Drug Abuse grants T32 DA007261 (AMT & AJB), R01 DA036583 (LJB), R01 DA14211 (EDK), R01 DA25931 (EDK) and K01 DA034035 (AJB), National Cancer Institute grant K05 CA139871 (TBB), National Institute of Heart, Lung, and Blood Disease grant R01 HL109031 (TBB), and the Taylor Family Institute for Innovative Psychiatric Research (GA). Genotyping services for the UW-TTURC sample were provided by the Center for Inherited Disease Research (CIDR) and funding support for CIDR was provided by NIH grant U01 HG004438 and NIH contract HHSN268200782096C to The Johns Hopkins University. Assistance with genotype cleaning was provided by the Gene Environment Association Studies (GENEVA) Coordinating Center (U01 HG004446). LC/MS/MS analysis carried out in the Analytical Biochemistry Core of the University of Minnesota Cancer Center, was supported in part by National Cancer Institute grant CA-77598.

**CONFLICT OF INTEREST**

Laura J. Bierut and Alison Goate are listed as an inventors on Issued U.S. Patent 8,080,371,"Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction.

![rs2266780 genotype associated with (A) deuterated (d~2~)-nicotine *N*-oxidation (d~2~-nicotine-*N*-oxide/(d~2~-nicotine + d~2~-nicotine-*N*-oxide + d~2~-cotinine + d~2~-*trans*-3\'-hydroxycotinine + d~2~-nicotine-glucuronide) 4 hours after oral administration, and (B) ad libitum smoked nicotine *N*-oxidation (nicotine-*N*-oxide/(nicotine + nicotine-*N*-oxide + cotinine + *trans*-3\'-hydroxycotinine + nicotine-glucuronide). The boxplots provide summaries of the data distributions for each group of (n) subjects. A box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles.](nihms835435f1){#F1}

![Aberrant *FMO3* splicing in human liver and cerebellum tissues by rs2266780 genotype. (A) Aberrant exon 2--4 splicing (skipping exon 3) versus correct exon 3--4 splicing in liver cDNAs, and (B) aberrant exon 6--8 splicing (skipping exon 7) versus correct exon 7--8 splicing in liver or (C) cerebellum cDNAs. The difference in PCR cycle times (ΔCt) for cDNAs for (n) samples divided by rs2266780 genotype. Relative expression, ΔCt, determined by subtracting the Ct value of the reaction using exon skipping primers from the Ct value of the reaction using correct splicing primers (see methods). The boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles. (D) The products of PCR primers\[[@R39]\] flanking regions of *FMO3* including exons 3 or 7 amplified from liver cDNAs heterozygous for s2266780 (AG), homozygous for the s2266780 major allele (AA) or from pooled cDNAs from eight liver samples of various genotypes.](nihms835435f2){#F2}

![Time to first, the interval in minutes that smokers report typically waiting before lighting their first cigarette after awakening in the morning, for (n) samples divided by rs2266780 genotype.](nihms835435f3){#F3}

![Direct activation and modulation of human α4β2 receptors by *trans*-nicotine-*N*-oxide. (**A**) Sample traces from *Xenopus* oocytes expressing human α4β2 nicotinic receptors in the stoichiometry of 3:2. Direct activation by 200 μM nicotine-*N*-oxide was minimal compared to the response to 1 mM ACh from the same cell. Co-application of 200 μM nicotine-*N*-oxide reduced the peak response to 1 μM ACh. (**B**) Sample traces from *Xenopus* oocytes expressing human α4β2 nicotinic receptors in the stoichiometry of 2:3. Direct activating and modulating effects of nicotine-*N*-oxide are qualitatively similar to those observed in (A). (**C**) Concentration-response relationships for nicotine-*N*-oxide-mediated modulation of currents elicited by 1 μM ACh in oocytes expressing α4β2 receptors in 3:2 or 2:3 stoichiometry. The data show the response ratio (peak amplitude in the presence vs. absence of nicotine-*N*-oxide) in %. All data points were collected from the same set of cells (5 for 3:2 and 4 for 2:3). Statistical analysis compares the response ratio to 100% (i.e., no effect) using a paired t-test. ns, not significant, \*\*, P\<0.01, \*\*\*, P\<0.001.](nihms835435f4){#F4}

###### 

The influence of *FMO3* and *CYP2A6* haplotype upon *in vivo* nicotine *N*-oxidation

  MAF[a](#TFN2){ref-type="table-fn"}   Phenotype                                                 Percent of total oral D2-nicotine converted to nicotine-*N*-oxide [b](#TFN3){ref-type="table-fn"} (n= 170 subjects/340 chromosomes)   Percent of total ad libitum smoked D0-nicotine converted to nicotine-*N*-oxide [c](#TFN4){ref-type="table-fn"} (n= 59 subjects/118 chromosomes)                                                
  ------------------------------------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ---- ---------------- ----------------------
                                       *CYP2A6* normal alleles [d](#TFN5){ref-type="table-fn"}   244                                                                                                                                   −1.8 ± 0.2                                                                                                                                        \<2x10^−16^            87   −1.0 ± 0.2       1.3x10^−8^
                                       *CYP2A6\*1A*                                              48                                                                                                                                    −1.5 ± 0.2                                                                                                                                        4.6x10^−11^            19   −1.1 ± 0.2       2.6x10^−7^
                                       *CYP2A6\*9*                                               22                                                                                                                                    −1.1 ± 0.3                                                                                                                                        3.1x10^−5^             4    −0.3 ± 0.3       0.4
  0.229                                *FMO3* hap 2 (K158)                                       78                                                                                                                                    −0.1 ± 0.1                                                                                                                                        0.4                    24   −0.2 ± 0.1       0.1
  0.179                                *FMO3* hap 3 (K158;G308)                                  61                                                                                                                                    −**0.6 ± 0.1**                                                                                                                                    **3.3x10**^−^**^5^**   26   −**0.6 ± 0.1**   **5.6x10**^−^**^6^**
  0.103                                *FMO3* hap 4 (M257)                                       35                                                                                                                                    0.0 ± 0.2                                                                                                                                         0.7                    18   0.0 ± 0.1        0.8
  0.056                                *FMO3* hap 5                                              19                                                                                                                                    −**0.5 ± 0.2**                                                                                                                                    **0.047**              4    −**0.9 ± 0.3**   **1.3x10**^−^**^3^**
                                       Total adjusted R^2^                                       0.40                                                                                                                                  0.58                                                                                                                                                                                           

Results of linear regression analyses treating *CYP2A6* null alleles (*CYP2A6\*2, \*4, \*12* and *\*38*) and *FMO3* haplotypes, including 1 (minor allele frequency = 0.426), as the reference. Genetic variables are coded as number of haplotypes per subject (0,1,2). Negative parameter estimates indicate reduced nicotine *N*-oxidation relative to the reference genotype.

*FMO3* haplotype minor allele frequency in subjects with measured D~2~-nicotine-*N*-oxide

Deuterated (d~2~)-(nicotine-*N*-oxide/(nicotine + nicotine-*N*-oxide + cotinine + *trans*-3\'-hydroxycotinine + nicotine-glucuronide))

Non-deuterated (d~0~)-(nicotine-*N*-oxide/(nicotine + nicotine-*N*-oxide + cotinine + *trans*-3\'-hydroxycotinine + nicotine-glucuronide))

number of alleles

all *CYP2A6* alleles excluding *CYP2A6\*1A, \*9*, and assumed null alleles *CYP2A6\*2, \*4, \*12* and *\*38*.

###### 

Nicotine *N*-oxidation activity in human and mouse microsomes and recombinant human enzymes

                                                                                *cis*-nicotine-*N*-oxide (pmol min^−1^ mg^−1^)[a](#TFN7){ref-type="table-fn"}   *trans*-nicotine-*N*-oxide (pmol min^−1^ mg^−1^)[a](#TFN7){ref-type="table-fn"}   *trans : cis*
  ----------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------
  Human brain[b](#TFN8){ref-type="table-fn"}                                    0.23 ± 0.01                                                                     0.22 ± 0.03                                                                       0.95
  Human astrocytes[c](#TFN9){ref-type="table-fn"}                               0.30 ± 0.11                                                                     1.25 ± 0.42                                                                       4.2
  Human liver[d](#TFN10){ref-type="table-fn"}                                   271 ± 30                                                                        10 400 ± 300                                                                      38.4
  Mouse[e](#TFN11){ref-type="table-fn"} brain[f](#TFN12){ref-type="table-fn"}   27.6 ± 0.8                                                                      1.1 ± 0.2                                                                         0.04
  Mouse[e](#TFN11){ref-type="table-fn"} liver[d](#TFN10){ref-type="table-fn"}   2 670 ± 150                                                                     1 090 ± 40                                                                        0.4
  FMO3 supersomes[g](#TFN13){ref-type="table-fn"}                               4 160 ± 1 090                                                                   473 000 ± 52 000                                                                  114
  FMO1 supersomes[g](#TFN13){ref-type="table-fn"}                               94 600 ± 4 540                                                                  4 280 ± 250                                                                       0.05

5 mM nicotine

1.5 mg/ml protein in incubation

1.0 mg/ml protein in incubation

30 μg/ml protein in incubation

pooled tissues from adult female CD1 mice

260 μg/ml protein in incubation

0.5 μg/ml protein in incubation
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